Dr. Lal Path Labs Ltd. (LALPATHLAB)
Press Release
Press Release - Q1FY27
- Revenue Rs 798 Cr +19.1% y-y; EBITDA Rs 247 Cr +28.7% y-y (margin 31.0%); PAT Rs 170 Cr +27.2% y-y (margin 21.4%)
- Interim dividend declared at 50% i.e. Rs 5 per share
- Cash and cash equivalents at Rs 1,693 Cr as of June 30, 2026
- Acquired 80% stake in Sunshine Healthcare Limited, Ghana, diagnostic business
- Acquired 30% stake in Neuome Technologies Pvt Ltd, sample preservation and biobanking solutions
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 LALPATHLAB — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add LALPATHLAB to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Dr. Lal Path Labs Ltd.
Important.
The summary above is generated automatically from Dr. Lal Path Labs Ltd.'s own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.